Therefore, this potent inhibitor has been the starting point of another round of medicinal chemistry optimization that has culminated in NVP-CGM097 (highly potent and selective MDM2 inhibitor), which is a compound currently under evaluation in a phase I clinical trial for cancer patients [54,55]. Here, MDM2 is linked to cancer.